Constellation Pharmaceuticals (NASDAQ:CNST) Lowered to “Hold” at ValuEngine

Constellation Pharmaceuticals (NASDAQ:CNST) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Wednesday, ValuEngine reports.

CNST has been the topic of several other reports. Zacks Investment Research cut Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Constellation Pharmaceuticals in a research report on Wednesday, June 5th. Finally, Royal Bank of Canada initiated coverage on Constellation Pharmaceuticals in a research note on Wednesday, September 4th. They set an “outperform” rating and a $20.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.80.

CNST traded up $0.42 during trading on Wednesday, hitting $8.07. 48,293 shares of the company traded hands, compared to its average volume of 66,531. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $208.39 million, a PE ratio of -1.61 and a beta of 4.95. The stock’s 50-day simple moving average is $8.09 and its two-hundred day simple moving average is $10.13. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $14.04.

Constellation Pharmaceuticals (NASDAQ:CNST) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Equities analysts expect that Constellation Pharmaceuticals will post -3.06 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its stake in Constellation Pharmaceuticals by 4,092.4% during the first quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock valued at $45,000 after purchasing an additional 3,233 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Constellation Pharmaceuticals by 16.9% in the 4th quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock worth $55,000 after buying an additional 1,987 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Constellation Pharmaceuticals in the 2nd quarter worth about $61,000. Wade G W & Inc. bought a new stake in shares of Constellation Pharmaceuticals in the 1st quarter worth about $166,000. Finally, Wells Fargo & Company MN raised its position in shares of Constellation Pharmaceuticals by 42.1% during the 2nd quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after buying an additional 4,132 shares in the last quarter. 65.71% of the stock is currently owned by institutional investors.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Further Reading: Net Margin

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.